4:58 PM
 | 
Nov 15, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

CHMP recommends Merck's Prevymis for CMV

EMA's CHMP recommended approval of oral and IV formulations of Prevymis letermovir (MK-8228; AIC246) from Merck & Co. Inc. (NYSE:MRK) to...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >